June 8, 2015 - StableBody Technologies, LLC to Provide Critical Leukocyte Depletion Reagent for IVDiagnostics, LLC Circulating Tumor Cell Program Read More>>>

StableBody Technologies, LLC (SBT) has agreed to supply IVDiagnostics, LLC (IVD) with a key critical leukocyte depletion reagent for IVD's Circulating Tumor Cell In-vitro Assay for an undisclosed period of time.  This is the first of many antibody fragment products developed by SBT, using its proprietary bioinformatics platform, for the SBT-IVD collaboration agreement signed in 2013.

February 26, 2013 - IVDiagnostics, LLC Enters into Collaboration Agreement with StableBody Technologies, LLC for Critical Reagent Development Read More>>>








February 26, 2013


Crown Point, Indiana


IVDIAGNOSTICS, LLC. (hereafter “IVD”) of Crown Point, Indiana, and StableBody Technologies LLC (hereafter “SBT”) of Madison, Wisconsin, announce their development agreement for a novel “Circulating Cancer Cell Detection System” (hereafter “CCCDS”).


The system, consisting of a diagnostic instrument platform by IVD and customized cancer biomarker reagents from SBT, is expected to produce a commercial product capable of identifying circulating cancer cells in human blood, non-invasively. Both companies will contribute necessary source funding and scientific expertise for the proprietary detection platform and necessary critical reagents for a commercial grade product offering.


IVD is a biotechnology company with considerable experience and intellectual property in the in-vitro cell detection technology field and the human cancer cell bio-marker field. IVD has developed a prototype platform for the intent of non-invasive cancer cell detection in human blood.

Mr. Szczepanski said 'IVDiagnostics looks forward to working with Stablebody Technologies in an effort to improve the diagnosis of Circulating Tumor Cells at earlier stages of cancer growth. By utilizing the IVDxTx platform together with SBT stable proteins we hope to better clarify and characterize the molecular diagnosis of metastatic disease and monitor patient progression via real-time analysis.'


SBT has considerable experience and intellectual property in the protein design and critical reagents field, including exclusive use of licensed human cancer cell biomarkers. SBT has development work underway for important biomarkers for cancer cells not previously available.


Mr. Horn commented “New, next generation reagents having high stability, sensitivity and specificity for particular disease indications, offer new tools for disease detection not previously possible.”

The Project plans the development completion of the CCCDS within one year of the Project initiation, with clinical evaluation and life science company commercialization licensing with two years of the Project start.  SBT and IVD will continue discussions toward a potential merger while engage on the CCCDS development project.


IVDiagnostics is located at the Northwest Indiana Purdue Technology Center. StableBody Technologies is located at the University of Wisconsin Innovation Center.

For further information, contact:


IVDiagnostics:                                    Frank Szczepanski, Co-Founder & Chairman
                                                            9800 Connecticut Drive, Crown Point, Indiana 46307
                                                            Phone: (219) 840-0007


StableBody Technologies:                  H. Rossiter Horn, Co-Founder and Chief Executive Officer
                                                            505 S. Rosa Road, Suite 109, Madison, Wisconsin 53719
                                                            Phone:  (608) 698-8445
December 11, 2012 - StableBody Technologies recognized in _In Business_ magazine. Check it out at Read More>>>

Check it out at

May 28, 2012 - SBT aquires Vascular Disrupting Assay to Test Reagents for Cancer Market Read More>>>

StableBody Technologies, LLC to Use Proprietary Technology to Develop Anti-Cancer Reagents

June 12, 2012

Madison, WI—StableBody Technologies, LLC (SBT) has acquired a methods patent for vascular mimicry (VM) factors expressed on tumor cells that will allow for the screening of vascular disrupting agents in a manner predictive of in-vivo responsiveness. This proprietary technology focuses on the diagnostic utility of tumor cell vascular mimicry to identify and generate novel therapeutic reagents – a new paradigm in cancer biology.  Vascular mimicry describes the ability of tumor cells to express vascular cell-associated biomarkers, (such as those associated with endothelial cells and their progenitors and other stem cells associated with embryogenesis and vasculogenesis) and form vasculogenic, perfusable networks in patient tumors.  These biomarkers are generally associated with poor clinical outcomes.  Vascular mimicry has been reported by numerous groups with many different tumor types associated with an aggressive tumor cell phenotype.

About SBT

STABLEBODY TECHNOLOGIES, LLC, formed in 2009, is a privately held protein engineering company based in Madison, Wisconsin. SBT is committed to become an industry leader in the stabilization and optimization of proteins, for applications in the treatment and detection of cancer as well as biothreat agent detection and countermeasures. SBT is focused on employing its’ core technology for the development of next generation stable proteins (NGSP).  The company has demonstrated extraordinary success in increasing thermal stability and affinity optimization of scFvs, making them suitable for field and laboratory conditions while not requiring freezing or refrigeration.  Additionally, the company develops reagents for detection that are capable of withstanding elevated temperatures in harsh environments while maintaining high specificity and sensitivity to their targets.


H. Rossiter Horn, RPh, COO


February 12, 2012 - Bolstering the Front Line of Biological Warfare Response Read More>>>

Bolstering the Front Line of Biological Warfare Response

DARPA advances sensitivity and durability of antibody-based biosensors to better protect warfighters; technologies to transition to DoD’s Critical Reagents Program 

Biological warfare agents pose more than a hypothetical threat to U.S. military servicemembers. Troops operate in hostile areas where they could come under attack from adversaries wielding bio-agents like anthrax and toxins. The first step in reacting to any such attack is knowing that it occurred. Quickly and accurately identifying the presence of airborne antigens can be difficult given their complexity, the presence of numerous similar microorganisms in the environment, and the fact that even minute quantities of a threat agent can cause infection.[i]  

The Department of Defense (DoD) employs antibody-based biosensors as its immediate tool for quickly detecting antigens—antibodies bind to antigens—but these sensors have functional limitations that can leave warfighters at risk. The two biggest liabilities involve stability and affinity. Stability refers to a sensor’s ability to continue functioning as required over time and despite environmental conditions. Affinity refers to the tightness of the bond between an antibody and an antigen; the higher the affinity, the more sensitive a biosensor is over a wider range of threats. Existing DoD biosensors, while effective, have restricted shelf lives, are quickly rendered inoperable by high temperatures and offer limited affinity.

DARPA launched the Antibody Technology Program (ATP) in 2009 to address the technological limitations of current antibody-based biosensors. The program set out with two primary goals: achieve revolutionary improvements in the stability of antibodies over time, even in extreme conditions; and control affinity in biosensors to enable detection of numerous antigens by a single unit. ATP ended in 2012 having achieved both goals and with a plan in place to transition the technologies to DoD’s Critical Reagents Program, part of the Joint Program Executive Office – Chemical and Biological Defense (JPE-CBD), for biosensor deployment throughout the military services.

Specifically, DARPA performers demonstrated the ability to increase antibody temperature stability at 70 degrees Celsius (158 degrees Fahrenheit) to 48 hours, up from the current limit of five to ten minutes.  When transitioned to DoD biosensors, these results are projected to eliminate the need for refrigeration while increasing the shelf life by a factor of 36, extending survivability at room temperature (approx. 25 degrees Celsius or 77 degrees Fahrenheit) from one month to approximately three years. DARPA also increased antibody affinity by a factor of 400, thus opening the door to vastly more sensitive, multiplexed biosensors that can test for numerous antigens.

Mildred Donlon, the DARPA program manager for ATP, explained the implications of the breakthroughs: “When you consider the locations of warfighters who have the most potential for biological weapons to be used against them, they are typically environments with extreme temperatures and harsh conditions, and the warfighters themselves are probably operating in small groups. If it’s going to be useful to these teams, DoD equipment needs to be ruggedized to survive conditions and be easy to use by non-experts. The ATP technology hits these goals.

“By removing temperature stability as a limiting factor, troops will now be able to carry sensors with them without worrying about refrigeration and wondering if the sensor will return an accurate reading. According to the Chemical Biological Medical Systems Joint Project Management Office at JPE-CBD, eliminating the need for cold-chain logistics in transport and deployment of sensors is estimated to save DoD in the range of $10 million per year,” Donlon said. “The new stability also means antibodies can be attached to new materials to make potentially more practical sensors to take the place of current beads and strips. Most importantly, by pairing more stable sensors with a huge increase in sensitivity, DARPA is giving troops the confidence to trust the results of what can be literally life-or-death measurements.”

ATP achieved these results by altering the amino acid sequences within the antibody molecules. Rather than creating an additive stabilizing material, ATP performers devised methods to make the altered amino acids an integral part of the structure of the antibody molecule.

“Antibody-based biosensors have been in use for roughly 30 years,” Donlon said. “DARPA used recent advances in understanding of protein structure and analysis to determine new ways to alter amino acids, integrate them into an antibody structure, and do so at a sustainable scale.”

DARPA partnered with the U.S. Army’s Edgewood Chemical Biological Center (ECBC) from the beginning of ATP, to first assist with evaluation of performer research proposals, then later in the program to provide ATP performers with unaltered antibodies, conduct testing on the performers’ altered antibodies, and validate results. To ensure that the production methods for modifying antibodies are scalable and cost effective, performers had to submit one-gram samples for testing. The positive results mean that existing DoD antibody stockpiles can be altered to incorporate the new properties of stability and high affinity. 

Program performers for ATP included: Affomix Corp. (Branford, Conn.), purchased by Illumina, Inc. (San Diego, Calif.); AnaptysBio, Inc. (San Diego, Calif.); the Naval Research Laboratory (Washington, District of Columbia); StableBody Technologies, LLC (Madison, WI.); The University of Texas at Austin (Austin, Texas); and the ECBC (Aberdeen, Md.), which participated as the validation laboratory. AxioMx, Inc. (Branford, Conn.) was created to rapidly generate high-quality recombinant antibodies.

[i] Committee on R&D Needs for Improving Civilian Medical Response to Chemical and Biological Terrorism Incidents, Institute of Medicine. 'Detection and Measurement of Biological Agents.' Chemical and Biological Terrorism: Research and Development to Improve Civilian Medical Response. Washington, DC: The National Academies Press, 1999.

August 3, 2010 - Selected as a winner in 2010 Biotechnology Vision Summit's Emerging Company Showcase. Read More>>>

BioForward Announces Winners of 2010 Biotechnology Vision Summit’s Emerging Company Showcase

MADISON, Wis.--(BUSINESS WIRE)--Six Wisconsin biotechnology companies have been selected the winners of BioForward’s second Emerging Company Showcase. The showcase is part of the Biotechnology Vision Summit 2010, being held on Wednesday, August 25, at the Madison Marriott West in Madison, Wis. and hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s biotechnology industry. The Emerging Company Showcase is sponsored by the University of Wisconsin-Madison Office of Corporate Relations and Tomotherapy.

“Collectively, these six emerging companies characterize the diversity and continued innovation of companies within Wisconsin’s thriving biotechnology industry.”

Each of these Wisconsin-based early stage companies were chosen because they have transitioned successfully out of research and development, with good proof of concept for their products. All of the winners are at the pre-commercialization or early-commercialization stage, and have made significant progress bringing their products to market. Each was judged to have a unique value proposition. This year’s Emerging Company Showcase winners are:

  • BIOFerm Energy Systems, Madison, Wis., is one of the leading providers of dry fermentation anaerobic digestion technology in the United States. BIOFerm™ will be building the first dry fermentation biogas plant in the US which will be located at the University of Wisconsin-Oshkosh.
  • BioInfoRx, Madison, Wis., BioInfoRx delivers novel web-based laboratory information management solutions to life science researchers. They offer a variety of ready-to-use products for laboratory management and data processing and develop custom systems for laboratories and facilities using BioInfoRx's innovative BxLIMS technology to make routine tasks as efficient as possible.
  • Eso-Technologies, Inc., Madison, Wis., Eso-Technologies, Inc is an early-stage medical device company launching an important new esophageal cardiac monitoring device for surgical and critical care applications within 3 years into a potential $2.0 billion market.
  • PercipEnz Technologies, Inc., Madison, Wis., PercipEnz Technologies develops and markets enterprise-class clinical and translational research management software. The company’s flagship product, OnCore®, is the nation’s most-widely adopted clinical research informatics platform amongst academic health centers and cancer centers doing clinical research. The OnCore platform is now adopted by 40% of the NCI-designated Cancer Centers doing clinical research.
  • StableBody Technologies, LLC, Madison, Wis., StableBody Technologies has optimized and dramatically improved recombinant antibody stability as a formulation tool for therapeutic and diagnostic markets thus accelerating the development process, enhancing product efficacy, facilitating manufacturing, and improving product use and application abilities.
  • Wisconsin Ability Network, Inc., Mosinee, Wis., Wisconsin Ability Network is a non-profit established to seek out opportunities that will bring production/service contracts to disability work centers within Wisconsin. They have recently partnered with New Composite Partners to manufacture Vegebone, an organic biodegradable dog bone product made with 100% plant-based material.

In addition to complimentary registration for the summit, the winners receive high-visibility exhibit space, recognition at one of the summit’s large plenary sessions and other premiums.

“We are delighted to have this particular set of companies recognized in our Emerging Company Showcase,” said Bryan Z. Renk, executive director of BioForward. “Collectively, these six emerging companies characterize the diversity and continued innovation of companies within Wisconsin’s thriving biotechnology industry.”

July 23, 2010 - Received Wisconsin Department of Commerce approval as a Qualified New Business Venture company eligible to extend tax benefits to investors. Read More>>>

Governor Doyle Announces StableBody Technologies, LLC, as Qualified New Business Venture


For Immediate Release: September 8, 2010
Contact: Tony Hozeny, Department of Commerce, 608-267-9661
Laura Smith, Office of the Governor, 608-261-2162

MADISON - Governor Jim Doyle announced today that StableBody Technologies, LLC, Middleton, Dane County, has received the Qualified New Business Venture (QNBV) certification from the Department of Commerce (Commerce). Commerce certified the company as eligible for up to $4 million in investment, which makes its investors eligible for a 25-percent tax credit on the amount they invest in the company.


'My administration is committed to helping businesses with their efforts to support new economic development opportunities,' Governor Doyle said. 'StableBody Technologies is built on a foundation of innovative technology and strong leadership. I am very excited to support a company that represents the future of Wisconsin's economy.'


'StableBody Technologies, LLC is excited to license this breakthrough technology from Argonne National Laboratory in Illinois and bring it to Wisconsin.' said H. Rossiter Horn, Founder and COO. 'We feel fortunate to be associated with many of the founders of the biotechnology industry of Wisconsin and a supportive, proactive Wisconsin Department of Commerce. SBT plan to make antibodies and proteins more robust so they may be adapted to more molecular uses in therapeutics and diagnostics.'


StableBody Technologies, LLC, formed in 2009, will commercialize a new technology in antibody research, development, and manufacturing. Antibodies are an important tool in biomedical research. The innate stability of a candidate antibody is a major contributor to its eventual success. StableBody Technologies, LLC will use new technology to promote the stabilization of target antibodies. The company relocated from Argonne, IL, to Middleton, WI.


When Governor Doyle took office, he understood that Wisconsin's research institutions were generating ideas and research that could give rise to successful companies and exciting new products - if our state could find a way to help researchers access capital and commercialize those products. The Governor developed a program now called Accelerate Wisconsin that provided angel and early stage fund investors with a 25-percent tax credit for investing in small and start-up Wisconsin technology firms.


When the program began in 2005, up to $3 million was available annually in angel investor tax credits and up to $3.5 million annually in early stage fund tax credits. The Governor has since signed legislation to raise these levels to $6 million annually for angel investors and $8 million annually for early stage fund investors in 2010, and $20 million and $20.5 million annually, respectively, in 2011 and beyond.


For additional information about the Qualified New Business Venture program, please visit

July 18, 2010 - DARPA Awards Contracts for More Rugged Reagents Read More>>>

              DARPA Awards Contracts for More Rugged Reagents

Madison, WI—StableBody Technologies, LLC has been awarded a Phase I contract with DARPA to produce thermally stable and affinity optimized antibodies for the detection of toxic substances and biothreat agents.

'The military often operates in challenging environments that can shorten the functional life of important reagents such as antibodies which are capable of detecting trace amounts of toxic substances,' according to H. Rossiter Horn, COO.  'Using our SBT-PEM Platform, we have created the potential to revolutionize the way antibodies are generated or improved, in this case enabling the generation of thermally stable antibodies with full retention of functionality.

'The results also may have meaningful clinical applications within the diagnostic and pharmaceutical industry for more flexible and less costly storage requirements for critical reagents such as therapeutic antibodies,' he said.

The award from the Defense Advanced Research Projects Agency has two phases over a 2 year period with a potential value of $2 million.

More robust antibody reagents allow for rapid detection of target molecules -- such as airborne bacteria and water contaminants -- and provide a higher level of sensitivity and specificity. The use of conventional antibodies in detection assays, however, has often been limited by stability and sensitivity issues such as exposure to heat.

About SBT


STABLEBODY TECHNOLOGIES, LLC was formed in 2009 to commercialize its novel StableBody Technology Protein Engineering Method (“SBT-PEM”) to provide Next Generation Protein Reagents (“NGPR”) to Life Science, Environmental Biosciences, Industrial and Research markets. The NGPR are robust proteins with increased stability and affinity, suitable for field and laboratory applications at ambient conditions.   This novel protein engineering technology enhances performance for currently expressed proteins as well as for new proteins, previously resistant to conventional modification. The SBT-PEM focuses on platforms and scientific strategies for designing efficient activity optimization against any specific target as well as for manufacturing, formulation and delivery.  For more information, visit



H. Rossiter Horn, RPh, COO


DISTRIBUTION STATEMENT A. Approved for public release; distribution unlimited.



StableBody Technologies Qualifies for Phase II Contract with DARPA to Develop Additional Robust, Affinity Optimized Antibodies.


July 29, 2011


Superior results lead to the successful completion of 1st year milestones and demonstrate applicability of Protein Engineering Method (PEM) platform for biodefense applications

MADISON, WI. – StableBody Technologies, LLC, a protein engineering company, announced that it has been awarded the Phase II contract from Defense Advanced Research Projects Agency (DARPA) to develop additional robust, affinity optimized antibodies for biodefense applications. SBT produced the most optimally functional antibody construct in the 12 month Phase I contract to earn the Phase II contract. The competitive Phase I contract, initiated in 2010 with DARPA, a U.S. Department of Defense agency, is focused upon generating antibodies that could be used to detect bioterror threats.


SBT’s proprietary SHM-PEM platform potentiates optimization of multiple properties, including thermal stability, expression, and functional activity, in parallel with affinity improvement. Aside from biodefense applications, the SBT-PEM is being used to improve the shelf life and in-vivo characteristics of clinical applications.


“We are excited that these positive results have qualified SBT for the Phase II contract with DARPA,” said H. Rossiter Horn, COO of StableBody Technologies. “The milestones achieved under this project demonstrate our ability to optimize the affinity and thermal stability of antibodies.”


About SBT


STABLEBODY TECHNOLOGIES, LLC was formed in 2009 to commercialize its novel StableBody Technology Protein Engineering Method (“SBT-PEM”) to provide Next Generation Protein Reagents (“NGPR”) to Life Science, Environmental Biosciences, Industrial and Research markets. The NGPR are robust proteins with increased stability and affinity, suitable for field and laboratory applications at ambient conditions.   This novel protein engineering technology enhances performance for currently expressed proteins as well as for new proteins, previously resistant to conventional modification. The SBT-PEM focuses on platforms and scientific strategies for designing efficient activity optimization against any specific target as well as for manufacturing, formulation and delivery. For more information, visit



H. Rossiter Horn, RPh, COO


DISTRIBUTION STATEMENT A. Approved for public release; distribution unlimited.



The Stability Fact Sheet:

Optimizing a method that works universally to improve recombinant antibody stability as a formulation tool for biomedical research, and as a manufacturing procedure for recombinant antibody products. Get the PDF file here.

Download File >>>


The Future of Protein Engineering

There is an unmet need to rationally adapt and optimize antibodies to new applications, rather than alter the environment in which they are employed. The SBT genome-based, proprietary strategies provide critical steps toward this goal.  Recent advances in protein structural modeling and synthetic biochemistry developed by SBT scientists afford a proprietary set of parameters for the routine and facile production of recombinant synthetic antibody fragments with improved stability and affinity profiles.  Efficient means of providing improvements in protein function and structure offer many competitive advantages over other recently developed methods.  Increased thermal stability alone provides extended product shelf life at room temperatures or higher, thus decreasing the requirement for cold chain storage and distribution.  Thus, the SBT core technology confers the robustness on these key protein reagents  contributing to a reduction of R&D costs, decreased probability of product failure, decreased development times and increased production scale-up.


StableBody Technologies, LLC
4675 Signature Drive

Middleton, WI 53562


H. Rossiter Horn, RPh

Chief Executive Officer